Retatrutide, a novel dual agonist of the GLP-1 binding site and glucose-dependent insulinotropic polypeptide (GIP) receptor , is demonstrating promising outcomes in preliminary human studies. Recent https://bookmarkfriend.com/story21397289/retatrutide-emerging-research-and-possible-clinical-roles